Mirati Therapeutics Stock Price, News & Analysis (NASDAQ:MRTX)

$28.70 +0.35 (+1.23 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$28.70
Today's Range$27.20 - $28.77
52-Week Range$2.70 - $30.50
Volume320,888 shs
Average Volume508,755 shs
Market Capitalization$765.27 million
P/E Ratio-9.23
Dividend YieldN/A
Beta2.1

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics logoMirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Debt-to-Equity RatioN/A
Current Ratio5.85%
Quick Ratio5.85%

Price-To-Earnings

Trailing P/E Ratio-9.22829581993569
Forward P/E Ratio-10.51
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book14.42

Profitability

Trailing EPS($3.11)
Net Income$-83,110,000.00
Net MarginsN/A
Return on Equity-96.82%
Return on Assets-82.29%

Miscellaneous

Employees52
Outstanding Shares26,990,000

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.81) by $0.16. View Mirati Therapeutics' Earnings History.

Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2018?

9 Wall Street analysts have issued 1 year price objectives for Mirati Therapeutics' stock. Their forecasts range from $5.00 to $21.00. On average, they anticipate Mirati Therapeutics' stock price to reach $14.75 in the next year. View Analyst Ratings for Mirati Therapeutics.

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:

  • 1. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)
  • 2. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (11/7/2017)

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,693,388 shares, an increase of 48.5% from the January 12th total of 1,140,675 shares. Based on an average daily trading volume, of 473,771 shares, the short-interest ratio is currently 3.6 days. Approximately 7.3% of the shares of the company are short sold.

Who are some of Mirati Therapeutics' key competitors?

Who owns Mirati Therapeutics stock?

Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.07%), BlackRock Inc. (1.89%), Jennison Associates LLC (1.81%), Geode Capital Management LLC (0.68%), Rock Springs Capital Management LP (0.67%) and Bogle Investment Management L P DE (0.51%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Who sold Mirati Therapeutics stock? Who is selling Mirati Therapeutics stock?

Mirati Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP and Broadfin Capital LLC. Company insiders that have sold Mirati Therapeutics company stock in the last year include Jamie Christensen and Tuesday Thirteen Inc. View Insider Buying and Selling for Mirati Therapeutics.

Who bought Mirati Therapeutics stock? Who is buying Mirati Therapeutics stock?

Mirati Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Rock Springs Capital Management LP, Bogle Investment Management L P DE, Artal Group S.A., SG Americas Securities LLC, EAM Investors LLC and Goldman Sachs Group Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Charles M Baum, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy Mirati Therapeutics stock?

Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of Mirati Therapeutics stock can currently be purchased for approximately $28.70.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $765.27 million. The biotechnology company earns $-83,110,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Mirati Therapeutics employs 52 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mirati Therapeutics (NASDAQ:MRTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.892.892.882.40
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.75$14.75$13.71$8.50
Price Target Upside: 14.24% downside14.24% downside22.08% downside77.08% upside

Mirati Therapeutics (NASDAQ:MRTX) Consensus Price Target History

Price Target History for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ:MRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018HC WainwrightBoost Price TargetBuy -> Buy$17.00 -> $21.00N/AView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$18.00HighView Rating Details
1/8/2018CannReiterated RatingBuy$18.00HighView Rating Details
12/21/2017CowenInitiated CoverageOutperformLowView Rating Details
11/14/2017Leerink SwannUpgradeMarket Perform -> Outperform$9.00N/AView Rating Details
10/12/2017SunTrust BanksReiterated RatingBuy$13.00N/AView Rating Details
9/19/2017CIBCInitiated CoverageOutperform -> Outperform$18.00LowView Rating Details
9/19/2017CitigroupReiterated RatingBuy$8.00 -> $16.00LowView Rating Details
8/4/2017Jefferies GroupSet Price TargetHold$5.00LowView Rating Details
11/18/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
11/4/2016WedbushReiterated RatingOutperform$12.00N/AView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00N/AView Rating Details
6/6/2016BarclaysLower Price TargetOverweight$41.00 -> $27.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Mirati Therapeutics (NASDAQ:MRTX) Earnings History and Estimates Chart

Earnings by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ MRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.81)($0.65)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.81)($0.74)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.78)($0.73)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.97)($0.99)ViewN/AView Earnings Details
11/3/2016Q3 2016($1.15)($0.97)ViewN/AView Earnings Details
8/4/2016Q2($1.15)($1.11)ViewN/AView Earnings Details
5/5/2016Q1($0.99)($1.13)ViewN/AView Earnings Details
3/9/2016Q4($1.03)($0.96)ViewN/AView Earnings Details
11/6/2015Q3 2015($0.88)($1.11)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.74)($0.95)ViewN/AView Earnings Details
5/6/2015Q1 2015($0.71)($0.77)ViewN/AView Earnings Details
3/11/2015Q414($1.00)($0.77)ViewN/AView Earnings Details
11/10/2014Q314($0.77)($0.72)ViewN/AView Earnings Details
8/8/2014Q214($0.69)($0.82)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.79)($1.01)ViewN/AView Earnings Details
3/18/2014Q413($0.66)($0.97)ViewN/AView Earnings Details
11/12/2013Q313($0.78)($2.95)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.59)($0.81)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.50)($1.00)ViewN/AView Earnings Details
3/13/2013Q4 2012($1.00)($1.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.50)($1.00)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.50)($0.75)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.50)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mirati Therapeutics (NASDAQ:MRTX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.79)($0.78)($0.79)
Q2 20182($0.87)($0.82)($0.85)
Q3 20182($0.95)($0.75)($0.85)
Q4 20182($0.91)($0.86)($0.89)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mirati Therapeutics (NASDAQ:MRTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mirati Therapeutics (NASDAQ MRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 67.85%
Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ MRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Jamie ChristensenSVPSell23,000$30.00$690,000.0010,877View SEC Filing  
1/26/2018Jamie ChristensenSVPSell12,500$26.11$326,375.0015,377View SEC Filing  
1/16/2018Jamie ChristensenSVPSell10,814$27.00$291,978.0013,691View SEC Filing  
1/11/2018Jamie ChristensenSVPSell14,725$22.99$338,527.756,395View SEC Filing  
11/16/2017Jamie ChristensenSVPSell10,275$18.00$184,950.0012,670View SEC Filing  
11/16/2017Venbio Select Advisor LlcMajor ShareholderBuy650,000$13.00$8,450,000.00View SEC Filing  
11/2/2017Jamie ChristensenSVPSell7,499$14.00$104,986.0010,169View SEC Filing  
10/4/2017Jamie ChristensenSVPSell4,000$14.00$56,000.00View SEC Filing  
9/21/2017Tuesday Thirteen Inc.Major ShareholderSell1,000$10.65$10,650.00View SEC Filing  
9/15/2017Jamie ChristensenSVPSell770$12.00$9,240.00View SEC Filing  
1/26/2017Ltd. BraslynMajor ShareholderBuy48,169$5.45$262,521.05View SEC Filing  
1/25/2017Ltd. BraslynMajor ShareholderBuy30,600$5.42$165,852.00View SEC Filing  
1/24/2017Ltd. BraslynMajor ShareholderBuy27,682$5.32$147,268.24View SEC Filing  
1/23/2017Ltd. BraslynMajor ShareholderBuy19,251$5.27$101,452.77View SEC Filing  
1/20/2017Ltd. BraslynMajor ShareholderBuy61,158$5.46$333,922.68View SEC Filing  
1/17/2017Ltd. BraslynMajor ShareholderBuy119,887$5.50$659,378.50View SEC Filing  
1/6/2017Boxer Capital, LlcMajor ShareholderBuy286,163$5.60$1,602,512.80View SEC Filing  
6/14/2016Charles M BaumCEOBuy20,000$7.05$141,000.0048,556View SEC Filing  
6/9/2016Bros. Advisors Lp BakerMajor ShareholderSell999,358$9.41$9,403,958.78137View SEC Filing  
6/7/2016Ltd. BraslynMajor ShareholderBuy376,902$9.96$3,753,943.92View SEC Filing  
5/6/2016Ltd. BraslynMajor ShareholderBuy65,782$18.21$1,197,890.22View SEC Filing  
3/28/2016Ltd. BraslynMajor ShareholderBuy20,848$19.36$403,617.28View SEC Filing  
3/18/2016Ltd. BraslynMajor ShareholderBuy1,166$19.34$22,550.44View SEC Filing  
1/15/2016Mark J. GergenCOOSell10,000$25.92$259,200.005,748View SEC Filing  
9/16/2015Bros. Advisors Lp BakerMajor ShareholderBuy150,000$45.00$6,750,000.00View SEC Filing  
5/26/2015Jamie ChristensenSVPSell4,750$28.07$133,332.50View SEC Filing  
3/5/2015Jamie ChristensenSVPSell6,000$25.41$152,460.00View SEC Filing  
2/19/2015Jamie ChristensenSVPSell4,750$22.84$108,490.00View SEC Filing  
2/3/2015Orbimed Advisors LlcMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
1/29/2015Bros. Advisors Lp BakerMajor ShareholderBuy425,000$20.00$8,500,000.00View SEC Filing  
7/1/2014Orbimed Advisors LlcMajor ShareholderSell107,332$21.66$2,324,811.12View SEC Filing  
11/26/2013Charles M BaumCEOBuy5,000$16.96$84,800.00View SEC Filing  
10/29/2013Orbimed Advisors LlcMajor ShareholderBuy125,000$17.50$2,187,500.00View SEC Filing  
10/24/2013Tang Capital Partners LpMajor ShareholderBuy57,143$17.50$1,000,002.50View SEC Filing  
9/20/2013Tang Capital Partners LpMajor ShareholderSell36,898$16.34$602,913.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mirati Therapeutics (NASDAQ MRTX) News Headlines

Source:
DateHeadline
Mirati Therapeutics, Inc. (MRTX) Given Consensus Recommendation of "Buy" by BrokeragesMirati Therapeutics, Inc. (MRTX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 20 at 2:34 PM
Mirati Therapeutics (MRTX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowMirati Therapeutics (MRTX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:17 PM
Free Research Reports on These Biotech Stocks -- Navidea Biopharma, Nektar Therapeutics, Mirati Therapeutics, and ... - PR Newswire (press release)Free Research Reports on These Biotech Stocks -- Navidea Biopharma, Nektar Therapeutics, Mirati Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - February 16 at 8:18 AM
Mirati Therapeutics (MRTX) Stock Rating Upgraded by BidaskClubMirati Therapeutics (MRTX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 9:10 PM
Mirati Therapeutics, Inc. (MRTX) Short Interest UpdateMirati Therapeutics, Inc. (MRTX) Short Interest Update
www.americanbankingnews.com - February 11 at 1:32 AM
Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare ConferenceMirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:54 AM
Mirati Therapeutics, Inc. (MRTX) SVP Sells $690,000.00 in StockMirati Therapeutics, Inc. (MRTX) SVP Sells $690,000.00 in Stock
www.americanbankingnews.com - February 8 at 6:16 PM
Mirati Therapeutics (MRTX) Upgraded to "Hold" at ValuEngineMirati Therapeutics (MRTX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 9:46 PM
Comparing Mirati Therapeutics (MRTX) & Tetralogic Pharmaceuticals (TLOG)Comparing Mirati Therapeutics (MRTX) & Tetralogic Pharmaceuticals (TLOG)
www.americanbankingnews.com - January 29 at 11:14 PM
Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 12,500 Shares of StockInsider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 12,500 Shares of Stock
www.americanbankingnews.com - January 29 at 6:32 PM
Mirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Buy" by BrokeragesMirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 26 at 9:52 AM
Sevion Therapeutics (SVON) & Mirati Therapeutics (MRTX) Financial ContrastSevion Therapeutics (SVON) & Mirati Therapeutics (MRTX) Financial Contrast
www.americanbankingnews.com - January 22 at 11:24 PM
Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 10,814 Shares of StockInsider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells 10,814 Shares of Stock
www.americanbankingnews.com - January 18 at 7:34 PM
Short Interest in Mirati Therapeutics, Inc. (MRTX) Grows By 31.9%Short Interest in Mirati Therapeutics, Inc. (MRTX) Grows By 31.9%
www.americanbankingnews.com - January 14 at 2:34 AM
Jamie Christensen Sells 14,725 Shares of Mirati Therapeutics, Inc. (MRTX) StockJamie Christensen Sells 14,725 Shares of Mirati Therapeutics, Inc. (MRTX) Stock
www.americanbankingnews.com - January 12 at 12:36 AM
Harry Boxer’s three health-care stocks to watch todayHarry Boxer’s three health-care stocks to watch today
finance.yahoo.com - January 10 at 4:57 PM
Mirati Therapeutics (MRTX) Receives "Buy" Rating from CannMirati Therapeutics (MRTX) Receives "Buy" Rating from Cann
www.americanbankingnews.com - January 8 at 9:44 AM
-$0.62 EPS Expected for Mirati Therapeutics, Inc. (MRTX) This Quarter-$0.62 EPS Expected for Mirati Therapeutics, Inc. (MRTX) This Quarter
www.americanbankingnews.com - January 6 at 5:10 PM
Comparing SIGA Technologies (SIGA) and Mirati Therapeutics (MRTX)Comparing SIGA Technologies (SIGA) and Mirati Therapeutics (MRTX)
www.americanbankingnews.com - January 4 at 7:34 PM
Mirati Therapeutics, Inc. (MRTX) Given Average Recommendation of "Buy" by BrokeragesMirati Therapeutics, Inc. (MRTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 1 at 10:22 AM
Comparing Mirati Therapeutics (MRTX) and ContraFect (CFRX)Comparing Mirati Therapeutics (MRTX) and ContraFect (CFRX)
www.americanbankingnews.com - December 31 at 5:30 PM
Mirati Therapeutics (MRTX) & XOMA (XOMA) Head to Head ComparisonMirati Therapeutics (MRTX) & XOMA (XOMA) Head to Head Comparison
www.americanbankingnews.com - December 29 at 3:24 PM
Cowen Begins Coverage on Mirati Therapeutics (MRTX)Cowen Begins Coverage on Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 21 at 4:28 PM
Benzingas Top Upgrades, Downgrades For December 21, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 21, 2017 - Benzinga
www.benzinga.com - December 21 at 9:54 AM
Reviewing XOMA (XOMA) and Mirati Therapeutics (MRTX)Reviewing XOMA (XOMA) and Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 19 at 7:30 PM
Mirati Therapeutics, Inc. (MRTX) Receives Average Recommendation of "Buy" from BrokeragesMirati Therapeutics, Inc. (MRTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 7 at 10:00 AM
Zacks: Analysts Expect Mirati Therapeutics, Inc. (MRTX) to Announce -$0.65 Earnings Per ShareZacks: Analysts Expect Mirati Therapeutics, Inc. (MRTX) to Announce -$0.65 Earnings Per Share
www.americanbankingnews.com - December 3 at 11:14 AM
Mirati Therapeutics (MRTX) Cut to "Sell" at ValuEngineMirati Therapeutics (MRTX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 6:30 AM
Contrasting Mirati Therapeutics (MRTX) and Mateon Therapeutics (MATN)Contrasting Mirati Therapeutics (MRTX) and Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 2 at 9:38 PM
Reviewing Soligenix (SNGX) and Mirati Therapeutics (MRTX)Reviewing Soligenix (SNGX) and Mirati Therapeutics (MRTX)
www.americanbankingnews.com - November 28 at 5:16 AM
Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Mirati Therapeutics, Inc. (MRTX)Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - November 23 at 1:14 PM
Insider Selling: Mirati Therapeutics, Inc. (MRTX) Major Shareholder Sells 1,000 Shares of StockInsider Selling: Mirati Therapeutics, Inc. (MRTX) Major Shareholder Sells 1,000 Shares of Stock
www.americanbankingnews.com - November 22 at 9:17 PM
Mirati Therapeutics Announces Closing of Public Offering of ... - PR Newswire (press release)Mirati Therapeutics Announces Closing of Public Offering of ... - PR Newswire (press release)
www.prnewswire.com - November 21 at 7:58 AM
Mirati Therapeutics (MRTX) Prices 2M Offering of Common Stock at $13/ShareMirati Therapeutics (MRTX) Prices 2M Offering of Common Stock at $13/Share
www.streetinsider.com - November 18 at 7:57 PM
FY2019 EPS Estimates for Mirati Therapeutics, Inc. (MRTX) Decreased by SunTrust BanksFY2019 EPS Estimates for Mirati Therapeutics, Inc. (MRTX) Decreased by SunTrust Banks
www.americanbankingnews.com - November 18 at 10:56 AM
Mirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 10,275 SharesMirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 10,275 Shares
www.americanbankingnews.com - November 17 at 8:58 PM
Brokers Set Expectations for Mirati Therapeutics, Inc.s FY2017 Earnings (MRTX)Brokers Set Expectations for Mirati Therapeutics, Inc.'s FY2017 Earnings (MRTX)
www.americanbankingnews.com - November 17 at 8:30 PM
ValuEngine Upgrades Mirati Therapeutics, Inc. (MRTX) to HoldValuEngine Upgrades Mirati Therapeutics, Inc. (MRTX) to Hold
www.americanbankingnews.com - November 16 at 11:34 PM
Mirati Therapeutics, Inc. (MRTX) Major Shareholder Acquires $8,450,000.00 in StockMirati Therapeutics, Inc. (MRTX) Major Shareholder Acquires $8,450,000.00 in Stock
www.americanbankingnews.com - November 16 at 4:22 PM
 Brokerages Anticipate Mirati Therapeutics, Inc. (MRTX) Will Post Earnings of -$0.75 Per Share Brokerages Anticipate Mirati Therapeutics, Inc. (MRTX) Will Post Earnings of -$0.75 Per Share
www.americanbankingnews.com - November 15 at 3:24 AM
Mirati Therapeutics, Inc. (MRTX) Upgraded at Leerink SwannMirati Therapeutics, Inc. (MRTX) Upgraded at Leerink Swann
www.americanbankingnews.com - November 15 at 12:58 AM
HC Wainwright Reiterates Buy Rating for Mirati Therapeutics, Inc. (MRTX)HC Wainwright Reiterates Buy Rating for Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - November 14 at 1:14 PM
Short Interest in Mirati Therapeutics, Inc. (MRTX) Declines By 29.9%Short Interest in Mirati Therapeutics, Inc. (MRTX) Declines By 29.9%
www.americanbankingnews.com - November 14 at 2:56 AM
Mirati Therapeutics, Inc. (MRTX) Given Consensus Recommendation of "Hold" by BrokeragesMirati Therapeutics, Inc. (MRTX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 9:54 AM
Reviewing Mirati Therapeutics (MRTX) & VBI Vaccines (VBIV)Reviewing Mirati Therapeutics (MRTX) & VBI Vaccines (VBIV)
www.americanbankingnews.com - November 11 at 5:28 AM
Mirati Therapeutics, Inc. Expected to Post FY2017 Earnings of ($2.86) Per Share (MRTX)Mirati Therapeutics, Inc. Expected to Post FY2017 Earnings of ($2.86) Per Share (MRTX)
www.americanbankingnews.com - November 6 at 4:14 AM
SunTrust Banks Weighs in on Mirati Therapeutics, Inc.s FY2017 Earnings (MRTX)SunTrust Banks Weighs in on Mirati Therapeutics, Inc.'s FY2017 Earnings (MRTX)
www.americanbankingnews.com - November 6 at 4:14 AM
FY2017 Earnings Estimate for Mirati Therapeutics, Inc. Issued By Leerink Swann (MRTX)FY2017 Earnings Estimate for Mirati Therapeutics, Inc. Issued By Leerink Swann (MRTX)
www.americanbankingnews.com - November 6 at 4:14 AM
Analysts Offer Predictions for Mirati Therapeutics, Inc.s FY2017 Earnings (MRTX)Analysts Offer Predictions for Mirati Therapeutics, Inc.'s FY2017 Earnings (MRTX)
www.americanbankingnews.com - November 6 at 4:14 AM
Mirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 7,499 SharesMirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 7,499 Shares
www.americanbankingnews.com - November 3 at 9:24 PM

SEC Filings

Mirati Therapeutics (NASDAQ:MRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mirati Therapeutics (NASDAQ:MRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mirati Therapeutics (NASDAQ MRTX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.